Bristol-Myers Squibb Co vs Virgin Galactic Holdings, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.74 (market cap $132.45B), while Virgin Galactic Holdings, Inc. trades at $3.29 (market cap $488.94M). The key difference: Bristol-Myers Squibb Co is far larger — about 270.9× Virgin Galactic Holdings, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 3.89% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| BMY | SPCE | |
|---|---|---|
Market Cap | $132.45B | $488.94M |
Sector | Health | Industrials |
52-Week High | $65.89 | $7.52 |
52-Week Low | $42.60 | $2.17 |
Enterprise Value | $166.44B | $588.79M |
Dividend Yield | 3.89% | — |
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →